Pre-made Imalumab biosimilar ( Whole mAb, anti-MIF therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-265
Anti-MIF therapeutic antibody (Pre-made Imalumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MIF therapeutic antibody (Pre-made Imalumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6foe:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Colorectal cancer;Malignant ascites|
|Conditions Discontinued||Solid tumours;Lupus nephritis|